Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
Users online: 3751  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page

Table of Contents 
Year : 2013  |  Volume : 58  |  Issue : 4  |  Page : 317-318
Authors' reply

Department of Dermatology, Dr. D.Y. Patil Medical College and Hospital, Nerul, Navi Mumbai, Maharashtra, India

Date of Web Publication25-Jun-2013

Correspondence Address:
Kiran Godse
Department of Dermatology, Dr. D.Y. Patil Medical College and Hospital, Nerul, Navi Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

How to cite this article:
Patil S, Sharma N, Godse K. Authors' reply. Indian J Dermatol 2013;58:317-8

How to cite this URL:
Patil S, Sharma N, Godse K. Authors' reply. Indian J Dermatol [serial online] 2013 [cited 2020 Aug 4];58:317-8. Available from:


We thank authors of this letter for their interest in our article and their critical appraisal of our work. We would like to offer certain clarification of the points they have raised in the letter. [1]

Regarding specific response parameters and patient specific parameters we acknowledge that we did not provide details in our article due to constraints of space. The same applies to not providing blood collection and serum preparation techniques. However, we would like to state that we did use the urticaria activity score (UAS) as a specific response parameter.

UAS showed a declining trend from baseline (mean 36 ± 6) to 4 weeks (mean 25 ± 5) and further decrease to 9 weeks (mean 10 ± 6, P = 0.001). Dermatology life quality index (DLQI) also showed a significant decline from baseline (mean 26 ± 6) to 9 weeks (mean 10 ± 6). The no. of antihistamine consumption at baseline (mean 7 ± 1) and 9 weeks (mean 2 ± 1, P = 0.001) also decreased accordingly (mean 2 ± 1, P = 0.001).

Thus summarize the result according to UAS: 45% patients had excellent response and 30% pt had moderate response and 25% pt had mild response at the end of 9 weeks.

Similarly, DLQI and the average no. of antihistamines use from baseline to 9 weeks had also declined significantly.

The thyroid profile showed deranged thyroid profile in 4 patients, but not associated with anti-microsomal thyroid antibody; along with it all patients were antinuclear antibody negative. As autologous serum was used and not involving foreign serum; hence, we did not think it economically feasible to do all tests by the author.

Regarding the procedure our method of collection of serum and injection of the same was based on standard and accepted techniques as mentioned by Bajaj et al. 5 ml blood was collected in a red topped vacutainer and then further centrifuged at 3,000 rpm, made into serum and 2.5 ml is injected deep intramuscularly immediately. No other special techniques were used for the collection and administration. [2]

The duration of auto-serum therapy was based on the work of Staubach et al. who found good results weekly injections for 8 weeks. [3]

Action of auto-serum therapy in chronic urticaria is based on the principle that it has immunomodulating effects that elicit a beneficial response. As mentioned in the article, it leads to desensitization by activating reticuloendothelial system with formation of specific antibodies. It is now believed that it affects immune parameters such as interleukin-10, T cell subpopulation and activation of macrophages. [4]

We acknowledge we did not mention the length of follow-up in our article and wish to express regrets for the same. Now, we would like to mention that the duration of follow-up ranged from 1 year to 3 years. We chose a longer follow-up duration to accurately assess the longevity of the suppressive effect of this therapy.

All patients were stopped with antihistamines and other immunosuppressive drugs 2 days prior the autologous serum skin test and during the treatment patients were given rescue antihistamine whenever required so that the average number of tablets required could be calculated and used to monitor the response to therapy.

In all standard references we pursued there were no significant side-effects detected. Hence, we feel that the safety and probably the efficacy of this therapy are self-evident. Obviously, this has to be validated by larger trials, which are double blind in nature.

We cannot deny that omalizumab is a well-tolerated and effective drug for chronic urticaria. However, beyond the reach of most of the Indian patients, we feel that using auto-serum therapy would be a cost-effective, cheap and safe way to treat chronic spontaneous urticariain patients who cannot afford omalizumab.

   References Top

1.Khan S. More robust evidence and safety checks are required before autologous serum therapy as treatment for chronic urticaria can be recommended. Indian J Dermatol 2013;58:316-7.  Back to cited text no. 1
  Medknow Journal  
2.Bajaj AK, Saraswat A, Upadhyay A, Damisetty R, Dhar S. Autologous serum therapy in chronic urticaria: Old wine in a new bottle. Indian J Dermatol Venereol Leprol 2008;74:109-13.  Back to cited text no. 2
[PUBMED]  Medknow Journal  
3.Staubach P, Onnen K, Vonend A, Metz M, Siebenhaar F, Tschentscher I, et al. Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: A placebo-controlled trial. Dermatology 2006; 212:150-9.  Back to cited text no. 3
4.Al Aboud K, Al Hawsawi K, Al Alaboud A, Ramesh V, Jain N. Blood transfusion and dermatology. Acta Dermatovenerol Alp Panonica Adriat 2006;15:20-4.  Back to cited text no. 4


Print this article  Email this article
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (980 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded50    
    Comments [Add]    

Recommend this journal